Studies how spinal muscular atrophy drugs affect muscle in patients

Trial details

Who runs it

St. Jude Children's Research Hospital

Trial code

NCT06532474

Record updated

9 July 2026

Original description

In this observational study, researchers are looking at the effects of spinal muscular atrophy (SMA) drugs on the muscles and nerve cells in patients with SMA.Read full original descriptionShow less

Pilot Study Exploring the Physiologic, Pharmacodynamic, and Clinical Responses of Skeletal Muscle in Patients With Spinal Muscular Atrophy Treated With SMN-Directed Therapies

In this observational study, researchers are looking at the effects of spinal muscular atrophy (SMA) drugs on the muscles and nerve cells in patients with SMA.

Primary Objectives

* To evaluate the feasibility and reliability of performing MR functional imaging in exercising muscle in patients with SMA. * To evaluate patients with SMA types 2 and 3 at baseline and longitudinally at 6 and 12 months

Secondary Objectives

* To describe the MR functional bioenergetics response in muscles in five potential groups of patients with spinal muscular atrophy: untreated, actively treated with nusinersen (Spinraza®) or onasemnogene abeparvovec (Zolgensma®), actively treated with risdiplam (Evrysdi®), switching from Spinraza or Zolgensma to Evrysdi and initiating combination therapy of Spinraza or Zolgensma with Evrysdi . * To identify changes in motor function in patients with SMA types 2 and 3 who initiate treatment with risdiplam. * To obtain biomarkers in blood, urine, and muscle tissue to provide proof-of-concept support for risdiplam effect on skeletal muscle. * To obtain quality of life and disability data from participants in this study.

Inclusion: Genetic confirmation of SMA with homozygous deletion of SMN1 or compound heterozygous deletion/mutation of SMN1; Two, three, or four copies of SMN2; Age 5 to 20 years; Non-ambulatory participants: maximum function sitting or standing with support, HFMSE score at screening between 10 and 45 points; Ambulatory participants: minimum function of independent walking, able to walk unassisted a minimum of 100 meters at screening, HFMSE score at screening between 40 and 66; SMN-directed therapy inclusion:; Current Evrysdi prescription (Group 1); Must have Evrysdi prescription through their treating physician; If initiating combined therapy using Evrysdi with Spinraza or Zolgensma, must have not started Evrysdi treatment OR; Current Spinraza or Zolgensma prescription (Group 2); For patients on Spinraza, must have been taking Spinraza for at least 12 months at screening (4 loading and 2 maintenance doses) and following the FDA-recommended dosing schedule; For patients on Zolgensma, must have been dosed at least one year prior to screening; Must have Spinraza or Zolgensma prescription through their treating physician OR; Changing from Spinraza or Zolgensma to Evrysdi (Group 3); For patients on Spinraza, must have been taking Spinraza for at least 12 months at screening (4 loading and 2 maintenance doses) and following the FDA-recommended dosing schedule; For patients on Zolgensma, must have been dosed at least one year prior to screening; Must have voluntarily decided to switch therapies based on discussion with their treating physician; Must have Evrysdi prescription through their treating physician but have not yet initiated treatment OR; Have never received any SMN-directed therapies (Group 4).

Exclusion: Any chronic medical condition, planned surgery, or treatment with a medication which would impact safety or participation of the study at the investigator's discretion; Any ferrous metal implants (e.g., spinal rods) that preclude testing in a MR scanner; Inability to perform reliably the motor function testing or the exercise testing in the MR scanner; Fat fraction > 35% in calf or bicep at screening MRI; Need for routine non-invasive ventilation support; Non-oral nutritional support, e.g., gastrostomy tube feeding.

ClinicalTrials.gov NCT06532474